Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
138,100
Employees138,100
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
138,100
Employees138,100

JNJ Key Statistics

Market cap
379.43B
Market cap379.43B
Price-Earnings ratio
17.11
Price-Earnings ratio17.11
Dividend yield
3.22%
Dividend yield3.22%
Average volume
13.20M
Average volume13.20M
High today
$159.44
High today$159.44
Low today
$153.77
Low today$153.77
Open price
$154.25
Open price$154.25
Volume
10.98M
Volume10.98M
52 Week high
$169.99
52 Week high$169.99
52 Week low
$140.68
52 Week low$140.68

JNJ News

TipRanks 10h
Unusually active option classes on open April 17th

Unusual total active option classes on open include: Energy Fuels (UUUU), Maplebear Inc (CART), Eli Lilly (LLY), Dollar General (DG), American Express (AXP), CV...

Benzinga 1d
Johnson & Johnson's Q1 Results, FY Guidance Highlight The 'Power Of The Pharma Portfolio'

Johnson & Johnson JNJ reported upbeat first-quarter results on Wednesday. Here are some key analyst takeaways. Goldman Sachs On Johnson & Johnson Analyst Asa...

Johnson & Johnson's Q1 Results, FY Guidance Highlight The 'Power Of The Pharma Portfolio'
TipRanks 2d
Johnson & Johnson price target raised to $169 from $164 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Johnson & Johnson to $169 from $164 and keeps an Equal Weight rating on the shares after the company posted a Q...

Analyst ratings

54%

of 24 ratings
Buy
45.8%
Hold
54.2%
Sell
0%

More JNJ News

TipRanks 2d
Hold Rating for Johnson & Johnson Amid Mixed Outlook and Macroeconomic Challenges

Bernstein analyst Lee Hambright maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) today and set a price target of $159.00. Lee Hambright’s...

TipRanks 2d
Johnson & Johnson: Balancing Stability and Risks Amid Tariff Challenges

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), boosting the price target to $169.00. Terence Fl...

TipRanks 2d
Cautious Outlook on Johnson & Johnson’s Orthopedic Segment Amid Slowed Growth and Competitive Pressure

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), with a price target of $...

TipRanks 2d
Johnson & Johnson’s Promising Outlook: Strong Q1 2025 Performance and Strategic Growth Initiatives Justify Buy Rating

Asad Haider, an analyst from Goldman Sachs, maintained the Buy rating on Johnson & Johnson (JNJ – Research Report). The associated price target remains the same...

TipRanks 2d
Johnson & Johnson’s Strong Start to 2025: Earnings Call Insights

Johnson & Johnson ((JNJ)) has held its Q1 earnings call. Read on for the main highlights of the call. The recent earnings call for Johnson & Johnson painted a...

TipRanks 2d
Johnson & Johnson’s Resilience and Strong Q1 Performance Justify Buy Rating Amid Challenges

Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Josh Jennings from TD Cowen main...

TipRanks 2d
JNJ Stock Slips as Investors Worry about the Impact of Tariffs

Johnson & Johnson (JNJ) beat Wall Street expectations in its first-quarter earnings report and raised its 2025 sales forecast by $700 million, even though sales...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.